Akari Therapeutics (AKTX) Equity Average (2012 - 2026)
Akari Therapeutics recorded quarterly Equity Average of $21.4 million in Q1 2026, down 16.28% quarter-over-quarter from $25.5 million in Q4 2025, and down 2.88% year-over-year from $22.0 million in Q1 2025.
Akari Therapeutics' Equity Average history runs 14 years deep, the most recent figure standing at $21.4 million for Q1 2026.
- In Q1 2026, Equity Average fell 2.88% year-over-year to $21.4 million; the TTM figure through Mar 2026 stood at $21.4 million (down 2.88% YoY), while the FY2025 annual figure was $25.3 million, up 129.8% from the prior year.
- Equity Average came in at $21.4 million for Q1 2026 at Akari Therapeutics, down from $25.5 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $25.5 million in Q4 2025 to a low of -$5.2 million in Q3 2024.
- A 5-year average of $9.4 million and a median of $6.4 million in 2022 frame the typical range for Equity Average.
- On a YoY basis, Equity Average climbed as much as 97193.75% in 2024 and fell as far as 447.26% in 2024.
- Akari Therapeutics' Equity Average stood at $5.1 million in 2022, then slumped by 100.16% to -$8000.0 in 2023, then jumped by 97193.75% to $7.8 million in 2024, then jumped by 228.39% to $25.5 million in 2025, then dropped by 16.28% to $21.4 million in 2026.
- According to Business Quant data, Equity Average over the past three periods registered $21.4 million, $25.5 million, and $24.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 1.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.35 Mn |
| Dec 31, 2025 | 25.51 Mn |
| Sep 30, 2025 | 24.15 Mn |
| Jun 30, 2025 | 23.68 Mn |
| Mar 31, 2025 | 21.99 Mn |
| Dec 31, 2024 | 7.77 Mn |
| Sep 30, 2024 | -5.20 Mn |
| Jun 30, 2024 | -3.63 Mn |
| Mar 31, 2024 | -1.89 Mn |
| Dec 31, 2023 | -8,000.00 |
| Sep 30, 2023 | 1.50 Mn |
| Jun 30, 2023 | 4.67 Mn |
| Mar 31, 2023 | 4.18 Mn |
| Dec 31, 2022 | 5.06 Mn |
| Jun 30, 2022 | 11.13 Mn |
| Mar 31, 2022 | 9.74 Mn |
| Dec 31, 2021 | 8.46 Mn |
| Sep 30, 2021 | 6.48 Mn |
| Jun 30, 2021 | 2.76 Mn |
| Sep 30, 2020 | 6.45 Mn |
| Jun 30, 2020 | 4.61 Mn |
| Mar 31, 2020 | 1.64 Mn |
| Dec 31, 2019 | 2.45 Mn |
| Sep 30, 2019 | 2.68 Mn |
| Jun 30, 2019 | 2.65 Mn |
| Mar 31, 2019 | 4.61 Mn |
| Dec 31, 2018 | 66.64 Mn |
| Sep 30, 2018 | 75.91 Mn |
| Jun 30, 2018 | 11.36 Mn |
| Mar 31, 2018 | 11.02 Mn |
| Dec 31, 2017 | 17.64 Mn |
| Sep 30, 2017 | 17.95 Mn |
| Jun 30, 2017 | 22.62 Mn |
| Mar 31, 2017 | 28.25 Mn |
| Dec 31, 2016 | 37.57 Mn |
| Sep 30, 2016 | 40.81 Mn |
| Jun 30, 2016 | 43.47 Mn |
| Mar 31, 2016 | 47.54 Mn |
| Dec 31, 2015 | 45.03 Mn |
| Sep 30, 2015 | 21.15 Mn |
| Jun 30, 2015 | 1.78 Mn |
| Mar 31, 2015 | 2.41 Mn |
| Dec 31, 2013 | -1.48 Mn |
| Dec 31, 2012 | -2.92 Mn |